When your spouse hesitates about a new depression treatment, it is easy to read that hesitation through your own fear. They say "I don't know," and you hear "I've given up." They ask a hard question about safety, and you hear resistance. Partners are not wrong to care this much. But some common interpretations make the conversation harder than it has to be.
Here are six beliefs partners often hold about a spouse's hesitation over ketamine-based depression care, each tested against the evidence and against our publisher's survey of 443 Midwest adults. Survey figures come from the final validated export; couples as such were not broken out.
Myth: "Hesitation means they don't really want to get better."
Reality: Hesitation is the most common response to this idea, not a sign of giving up. Asked how a ketamine option for depression or PTSD first struck them, respondents most often chose "cautious but open," chosen by a third of the sample, 34 percent. Another 18 percent were hopeful or curious. Firmly negative reactions came to just 9 percent.
Wanting to get better and wanting to be careful are compatible. A spouse who asks what a session involves, what the side effects are, and whether it is safe is showing the kind of engagement clinicians hope to see.
Myth: "If I explain it well enough, they'll say yes."
Reality: Good information helps, but partners are rarely the ones who close this decision. The deciding voice, for 74 percent of our respondents, was their own doctor's recommendation. Friends and family, spouses included, were chosen by 18 percent. Even for spouses, parents and other kin of veterans or first responders, a group of 156 people in our sample, the doctor still led at 73 percent.
That is not a knock on you. It means your explanation works best as a bridge to the doctor, not a substitute. "Would you want to ask your doctor about it?" is often more persuasive than a perfect summary.
Myth: "I should keep my worry to myself so I don't add pressure."
Reality: Hiding worry entirely can backfire. Your spouse may sense it anyway and feel shut out. There is a middle path: say what you have noticed and how you feel, without attaching a demand.
"I've been worried about you. I'm not asking you to do anything. I just wanted you to know I see how hard this is."
That kind of statement opens a door without pushing anyone through it.
Myth: "It's ketamine, so any version is dangerous and addictive."
Reality: Ketamine and esketamine do carry real risks, including potential for misuse, and that is exactly why the approved version is so tightly controlled. The FDA approved esketamine, sold as Spravato, for two adult groups: people whose depression has not yielded to earlier treatment, and people facing major depression together with acute suicidal thinking or behavior. Nobody but a certified center may give it, and staff keep the patient under watch for a minimum of two hours per dose. It never goes home with the patient.
That is very different from ketamine used recreationally, and different from off-label IV infusions or at-home ketamine prescribed online. The FDA has warned specifically about risks of unmonitored at-home use. Your spouse's concern about safety is legitimate. The answer is not "it's fine," it is "here is how the approved version is controlled, and a doctor can tell you whether it fits you."
Skepticism is widespread, by the way. A fifth of our respondents, 21 percent, called their first reaction skeptical. Your spouse is in good company. If they want to see how the approved treatment is handled, Brain Recovery Centers covers Spravato's supervised sessions in plain terms.
Myth: "At-home treatment would be easier on us, so it's the better choice."
Reality: Easier logistics are appealing, especially when you are the one doing the driving. Preferences vary: our survey found an in-person clinic favored by 44 percent, at-home telehealth by 22 percent, and 23 percent for starting in a clinic before shifting care home. But convenience is not the same as appropriateness. At-home ketamine is off-label for depression and lacks in-person monitoring. Esketamine is never given at home.
If the in-clinic schedule feels impossible, say so to the clinician. They can talk through options, alternatives, and centers with better hours. That is a better route than picking a product because it is easier.
Myth: "If it doesn't work right away, it failed, and so did we."
Reality: Response to any depression treatment varies. Some people notice changes early, others take longer, and some do not respond. The treating clinician tracks progress over weeks and adjusts the plan. And if a treatment does not help, that says nothing about your spouse's effort or your support. Treatment-resistant depression is, by definition, hard to treat.
It helps to agree ahead of time not to score each session. Let the clinician be the one who evaluates progress.
Partners also need somewhere to put their own weight. Weeks of driving, watching, and hoping can wear anyone down, and resentment tends to leak into conversations when it has no other outlet. A trusted friend, a support group for families, or your own counselor gives that strain a place to go that is not your spouse. Looking after yourself is part of what keeps you steady for them.
What does help
- Ask what the hesitation is about. Safety, cost, time, stigma, and fear of feeling out of control each call for different answers.
- Offer logistics, not arguments. Rides, childcare, and calling the insurance company are concrete. An esketamine patient is off the road until the day after a session, once they have slept.
- Check coverage if invited. Coverage was the top priority in our survey, with 85 percent ranking it in their top two.
- Respect "not now." A cautious person who feels respected is more likely to come back to the question.
Whether esketamine or any treatment suits your spouse is a question for their clinician. This article is about communication, not medical advice.
If your spouse brings up suicide, or you sense they are not safe, reach out to 988 by phone or text right away. You may contact the Suicide and Crisis Lifeline for them, whatever the hour.
Methodology
The study was ordered and financed by our publisher and run through Pollfish's consumer panel. It stopped accepting answers on June 23, 2026, with 443 finished, all from adults 18 to 64 across Minnesota, Oklahoma, Missouri, Ohio, Iowa, Indiana, Kansas, Wisconsin, Nebraska, and Illinois. Figures are drawn from the validated final export of the panel.